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Tana Tandarić 1, Alja Prah 2,3, Jernej Stare 2, Janez Mavri 2 and Robert Vianello 1,*
1 Division of Organic Chemistry and Biochemistry, Rud̄er Bošković Institute, Bijenička Cesta 54,
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Abstract: Monoamine oxidases (MAOs) catalyze the degradation of a very broad range of biogenic
and dietary amines including many neurotransmitters in the brain, whose imbalance is extensively
linked with the biochemical pathology of various neurological disorders, and are, accordingly, used as
primary pharmacological targets to treat these debilitating cognitive diseases. Still, despite this
practical significance, the precise molecular mechanism underlying the irreversible MAO inhibition
with clinically used propargylamine inhibitors rasagiline and selegiline is still not unambiguously
determined, which hinders the rational design of improved inhibitors devoid of side effects current
drugs are experiencing. To address this challenge, we present empirical valence bond QM/MM
simulations of the rate-limiting step of the MAO inhibition involving the hydride anion transfer
from the inhibitor α-carbon onto the N5 atom of the flavin adenin dinucleotide (FAD) cofactor.
The proposed mechanism is strongly supported by the obtained free energy profiles, which confirm
a higher reactivity of selegiline over rasagiline, while the calculated difference in the activation Gibbs
energies of ∆∆G‡ = 3.1 kcal mol−1 is found to be in very good agreement with that from the measured
literature kinact values that predict a 1.7 kcal mol−1 higher selegiline reactivity. Given the similarity
with the hydride transfer mechanism during the MAO catalytic activity, these results verify that
both rasagiline and selegiline are mechanism-based irreversible inhibitors and offer guidelines in
designing new and improved inhibitors, which are all clinically employed in treating a variety of
neuropsychiatric and neurodegenerative conditions.
Keywords: irreversible inhibition; monoamine oxidase; hydride transfer; antiparkinsonian drugs;
neurodegeneration; flavoenzymes
1. Introduction
Monoamine oxidases (MAOs) are flavoenzymes that metabolize a wide range of biogenic and
dietary amines, including monoamine neurotransmitters, such as dopamine, serotonin, and adrenaline,
in both the central nervous system and peripheral tissues [1]. Proper degradation of these molecules is
responsible for the stable function of synaptic neurotransmission, resulting in a healthy brain condition.
Since different concentrations of these small monoaminergic neurotransmitters influence our mood and
emotions, as well as the control of motor, perceptual, and cognitive functions, any imbalance in their
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concentration leads to the development and progression of a number of, if not all, neuropsychiatric
and neurological diseases.
There are two known isoforms of the MAO enzyme—MAO A and MAO B [2,3]—which share
around 70% sequence identity and the same FAD cofactor covalently attached at a conserved cysteine
residue [4]. Their active site cavities are placed deep inside the enzyme, and differ in volume and shape
between isoforms [5], which results in different substrate and inhibitor affinities [6]. The chemical
reaction catalyzed by both MAO isoforms involves the oxidation of the amine moiety via oxidative
cleavage of the substrate α-CH bond which consequently generates an imine intermediate. This step
is accomplished by the reduction of FAD to FADH2 that is followed by reoxidation back to FAD
with molecular oxygen and a simultaneous H2O2 release. The imine intermediate is hydrolyzed
nonenzymatically to the corresponding aldehyde and ammonia (with primary amines) or a substituted
amine (from secondary amines) [7]. The overall catalytic MAO reaction is given as:
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Figure 1. Chemical structure of the MAO B irreversible inhibitors and the FAD cofactor discussed in 
this work. The relevant atom labeling used throughout the text is also indicated. 
Inhibiting MAO B prolongs the half-life of dopamine in neurosynapses and extends its 
neurotransmission effect for the improvement of motor symptoms. In addition, it also prevents the 
MAO B-mediated oxidative damages in neurons [25,26], further prompted by the fact that more than 
80% of MAO in the human brain is of the B subtype [27]. Despite the facts listed above, MAO B 
inhibition drugs are still connected with significant adverse effects [27,28]. Furthermore, it is worth 
stressing that these two drugs are used only in symptomatic therapy, and they do not treat the cause 
of disease as dopaminergic agonists and L-DOPA. These facts underline the necessity for the design 
of new and more potent compounds devoid of any side reactions. 
All products of the MAO-mediated reactions are highly reactive species, and include a number of
potentially neurotoxic agents [8–10]. Because of that, constant excessive activity of MAO enzymes
may lead to mitochondrial damages which lead to the cell damage and dysfunction, resulting in
neurodegenerative disturbances. These premises are the main reason why MAO inhibition is recognized
as an important tool in the therapy of various psychiatric and neurological diseases, ranging fr m
mood disorders to Parkinson’s (PD) [11] and Alzheimer’s diseases (AD). Additional studies on MAO
knock-out mice [12,13] have revealed that the inactivation of this enzyme produces a n mber of
functional and behavioral changes, some of which are interesting for therapeutical use. The modulation
of the brain and behavior induced by MAO inhibitors [14] made the design of new and more potent
MAO inhibitors—one of the central topics of interest for both academia and industry over the last
60 years [15–20].
First discovered MAO inhibitors were the nonselective reversible inhibitors ipronazid [21] and
phenelzine, yet these compounds were shown to be associated with diverse ad erse effects, including
fatal liver toxicity [22] and the so-called “cheese reaction”, consisti g of severe, potentially lethal
hypertensive crises following the consumption of foods rich i amine tyramine [23], such as cheese
and red wine. These side effects are mainly produced by intestinal MAO A inhibition, since the
tyramine oxidation occurs exclusively by i testinal MAO A, which prompted research to develop
and characterize selective i hibitors. Along these premises, selective MAO B inhibitors, such as
selegiline (SEL) and rasagiline (RAS) (Figure 1), d not have such high incidence for fatal side effects,
which warrants their use without the restriction of a low-tyramine diet [24].
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inhibition drugs are still connected with significant adverse effects [27,28]. Furthermore, it is worth
stressing that these two drugs are used only in symptomatic therapy, and they do not treat the cause of
disease as dopaminergic agonists and L-DOPA. These facts underline the necessity for the design of
new and more potent compounds devoid of any side reactions.
The majority of MAO inhibitors in the current use are mechanism-based irreversible
inhibitors [11,29]. These drugs form a covalent bond with the enzyme, preventing further catalytic
activity, which is the most successful way of inhibiting MAO B in vivo [30,31]. Selegiline (L-deprenyl,
SEL) was the first such irreversible drug to be commercially used and has been on the market since the
late 1980s [32]. Its adduct with the N5 atom on FAD has been identified both chemically [33] and in the
crystal structure of the inhibited MAO B [34,35]. However, SEL is linked with a variety of side effects,
mainly caused by its major L-amphetamine-like metabolite, which can cause appetite suppression,
insomnia, and increased irritability [36,37]. In addition to that, amphetamines inhibit dopamine’s
transport to vesicles [38,39], which potentiate autooxidation in the cytoplasm [40]. This process
provides an additional source of the reactive oxygen species.
On the other hand, its propargyl analogue rasagiline (RAS) [41] was introduced to the market in
the first decade of the last century. RAS features the same mechanism of action, but, unlike SEL, it has
a much more favorable degradation inside of the human body. Not only are its metabolites linked with
significantly less side effects, they also behave in a neuroprotective way [42,43]. The main metabolic
product of RAS, 1-aminoindane, is proven to increase neuron life span, thus allowing a lower daily
dose. All these reasons explain why RAS is widely used nowadays.
Clinical practice confirmed that propargylamine MAO B inhibitors are effective and safe
medications that provide symptomatic benefits for PD patients from early to late stages of disease [44].
Because of this reason, a broad spectrum of therapeutic possibilities has been developed. Solutions
such as the transdermal administration, as well as prodrugs which are converted to active inhibitors
by brain enzymes that avoid problems with the lipophilicity, are promising directions for the future.
Over recent years, researchers developed many classes of potent and more selective
compounds [45–50]. Additionally, many efforts were involved in understanding structural differences
between MAO isoforms [51] that affect their selectivities. However, for a rational prediction of more
effective systems, the details of a precise chemical mechanism of the inhibition reaction are crucial,
and those are still missing. This would enable researchers to design mechanism-based drugs as
transition-state analogues that are likely to improve the selectivity and efficacy in neurodegenerative
diseases, which might allow for the use of lower therapeutic doses, thus strongly diminishing possible
adverse effects.
In our recent work [52], we performed molecular dynamics simulations [53] to investigate
the binding of SEL and RAS within the MAO B active site and identified residues predominantly
responsible for the successful binding. In addition, the calculated MM-GBSA binding free-energies
effectively reproduced a trend in the measured Ki and IC50 data, and thus confirmed that SEL binds
better due to its bigger size and flexibility, allowing it to optimize hydrophobic C–H···π and π···π
interactions with residues throughout both of the enzyme’s cavities, particularly with FAD, Gln206
and four active site tyrosines (Tyr435, Tyr398, Tyr60, Tyr326). In this way, SEL is able to overcome
a larger ability of RAS to form hydrogen bonds that only position it in less reactive orientations for
the subsequent inhibition reaction. More importantly, this was followed by the quantum mechanics
(QM) cluster calculations [54] at the DFT level, which revealed that the MAO inactivation proceeded
through a three-step reaction, where, in the rate-limiting first step, the MAO enzyme used the FAD’s
N5 atom to abstract a hydride anion from the inhibitor’s α-CH2 group (Figure 2), being in a full
analogy with the MAO catalytic mechanism [55–58], thus confirming that both SEL and RAS are
mechanism-based inhibitors. The complete reaction profile led from the bound inhibitors to the
corresponding N5(FAD)-adducts, the latter being in excellent agreement with the crystallographic
data on the inhibited enzyme, and further confirmed a better reactivity of SEL through both its lower
activation barrier and higher overall exergonicity [52]. Still, although the obtained relative difference
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in the activation free energies among inhibitors of ∆∆G‡ = 1.2 kcal mol−1 was found to be in excellent
agreement with the measured kinact values, which predicts a difference of ∆∆G‡EXP = 1.7 kcal mol−1,
the absolute values of ∆G‡(SEL) = 27.9 kcal mol−1 and ∆G‡(RAS) = 29.1 kcal mol−1 clearly exceeded
those predicted experimentally, although these were significantly lower than those calculated for
several alternative mechanistic scenarios. Still, the overestimated barriers are most likely due to the
known limitations of the employed cluster calculations that consider only a truncated part of the
enzyme; while the rest of the enzyme environment was accounted through the polarized continuum
approximation [59–66], requiring a fully featured treatment of the solvated enzymatic surroundings,
which is known to significantly affect the active site, mainly via electrostatic interactions. To overcome
these, here, we utilized the multiscale QM/MM approach, where the quantum subsystem was described
by the Empirical Valence Bond (EVB) methodology [67] in conjunction with an all-atom classical
representation of the hydrated enzyme. The purpose of this work was to attain a much better absolute
agreement in the calculated kinetic parameters with experimentally measured data, thus further
confirming the validity of the proposed hydride transfer mechanism in the case of the clinically
employed inhibitors selegiline and rasagiline.
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the irreversible inhibition of MAO enzymes with propargylamine inhibitors based on a direct hydride
abstraction studied here, which ultimately results in the inhibitor–FAD flavocyanine adduct as shown
in ref. [52].
2. s lts a isc ssion
Selegiline is a weak base with the experimentally determin d pKa value of 7.44 for the protonation
of its amino group in the aqueous solution [68]. This i dicates that, und r p ysiological conditions
of pH = 7.4, selegiline assumes a pr ctically equal population of its nionized and monocationic
protonation states. While we were not able to locate the corresponding literature ata for rasagiline,
we c n assume that its pKa value should be roughly th same. Our e rlier mechanistic propo al
required unionized inhibitors to underg the MAO inhibition [52], since it is significantly e sier
to d tach the hydride anion from the neutral system and generat the carbocation, tha it is from
the already monocati i system that is transformed into dicationic ompounds upo the hydride
abstraction. This is justified cons dering th men ioned pKa value for selegilin be ng close to the
physiological pH v ue, but also knowing the hydrophobic nature of the MAO active site, wh ch was
clearly demonstrate xperimentally [5,34] a d confirmed computationally [69]. Once p aced within
such a hydrophobic environment, th amino groups within investigated inhibitor will likely experience
a reduced basicity making their unionized analogues the predominan protonatio forms prior to
reacting with the FAD cofactor. Even if that would not b the case, such a deprotona ion n ea ily be
achieved by the active site water molecules with a cost of only a few kcal mol−1 [69,70]. I this context,
we utilized neutral SEL and RAS in all subs quent calculations, a d our DFT r sults with implicit SMD
solvation for their aqueous phase re ctivity are p esented in Tabl 1.
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Table 1. Relative Gibbs free energies for the relevant states of the reference aqueous-phase hydride
abstraction reaction among rasagiline or selegiline and lumiflavin calculated at the (SMD)/M06–2X/6–31
+ G(d,p) level of theory. The derived EVB off-diagonal coupling term (Hij) and the solution-phase shift
(α0) are also presented. All values are in kcal mol−1.
Inhibitor ReactantComplex
Transition
State Intermediate
Hij α0
Rasagiline 0.0 30.60 19.18 44.34 106.7
Selegiline 0.0 31.11 17.29 43.59 80.40
In a reference reaction between each inhibitor and lumiflavin in water (Table 1), the investigated
hydride abstraction reaction was a one-step process, which started from the unionized reactants and
resulted in the carbocationic inhibitor at the C(α) position and the anionic cofactor featuring a newly
formed N(5)–H bond (Figure 2). Interestingly, the reaction was kinetically slightly more favorable
for RAS, as its activation free energy was, by ∆∆G‡ = 0.51 kcal mol−1, lower than that for SEL. In the
transition state structure, the transferring hydride anion was placed between the leaving α-carbon and
the accepting N5 atom, with bond distances of 1.45 and 1.22 Å for RAS, respectively, being similar at
1.43 and 1.23 Å in SEL, in the same order. Specifically, this resulted in the activation free energy for
this process of 30.6 kcal mol−1 in RAS (νimag = 1351i cm−1), which increased to 31.1 kcal mol−1 in SEL
(νimag = 1390i cm−1). The latter suggests a moderately higher reactivity for RAS in the aqueous solution,
which would be different from the trend observed within the MAO B active site. Still, it is very likely
that a much simpler and highly polar aqueous environment favors hydride abstraction from a system
with a more polar secondary amine moiety in its immediate vicinity, as in RAS, than with a more
hydrophobic tertiary amine, as in SEL. Nevertheless, the thermodynamic picture of the investigated
reaction is in line with the expected situation in the enzyme, as the overall reaction free energy was,
by ∆∆GR = 2.1 kcal mol−1, more favorable for SEL. Subsequently, the same reacting system was
immersed in the explicit aqueous solution and submitted to the free-energy calculations with the
Q5 software, in order to derive the off-diagonal coupling term (Hij) and the solution-phase shift (α0)
for each inhibitor (see the Materials and Methods section later), to be utilized in the corresponding
simulations within the enzyme environment (Table 1).
The reaction profiles for the reaction in the MAO B active site are presented in Figure 3. Given that
each profile consisted of 10 distinct trajectories, corresponding to different initial inhibitor configurations,
we can safely state that all performed simulations were well-converged and pointed to consistent
conclusions. The calculated activation free energies of ∆G‡(RAS) = 27.6 and ∆G‡(SEL) = 24.5 kcal mol−1
indicated a higher reactivity of SEL, being in excellent agreement with the determined kinact values of
0.99 min−1 for SEL [71] and 0.0533 min−1 for RAS [72]. Even more so, these experimental parameters
translated to a difference in the activation free energy of 1.7 kcal mol−1 in favor of SEL, which was
nicely matched by our calculations of ∆∆G‡ = 3.1 kcal mol−1 here, thus lending to a strong credence to
the presented results. In line with that, the calculated reaction free energies also favored the inhibition
reaction with SEL, as the hydride abstraction was significantly more exergonic with that inhibitor
(∆∆GR = −8.2 kcal mol−1). Interestingly, these value were between 5 and 12 kcal mol−1 more exergonic
than those in water (Table 1), suggesting that the charged intermediates formed upon the H– transfer,
were better stabilized within the enzyme than in the aqueous solution, as already seen with several
MAO substrates [55–58].
On the other hand, if we consider the calculated activation free energies between the aqueous
solution and the enzyme environment, we observe that MAO B lowered the inactivation barrier by
2.97 kcal mol−1 for RAS, and as much as 6.64 kcal mol−1 for SEL (Figure 4). By employing the transition
state theory, the corresponding increase in the reaction rate constant could, therefore, be estimated
to between 2 and 5 orders of magnitude at room temperature, meaning that the reaction within the
enzyme proceeded significantly faster relative to the reaction in water. To put these numbers in
a proper context, let us mention that our earlier work demonstrated that the catalytic effect of the
Int. J. Mol. Sci. 2020, 21, 6151 6 of 13
MAO B enzyme was much larger—by 9 orders of magnitude for the MAO B catalyzed dopamine
degradation [56], relative to the same process in water, which is reasonable given that the structure of
the enzyme is evolutionally optimized for its physiological catalytic role, rather than for its irreversible
inactivation. In this context, it is interesting to note that the active site of MAO B facilitated the
inhibition reaction with SEL much more, which was able to make use of the enzyme environment
to overcome its lower intrinsic hydride-abstraction tendency over RAS, as evidenced with results in
a pure aqueous solution (Table 1). This again confirms an earlier observation [52] that, for a successful
design of novel inhibitors based on the propargylamine functionality, it is likely to be beneficial to
have a tertiary instead of a secondary amino group within the structure.
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located about halfway between the reactive C(α) atom of each inhibitor and the N5 ato on flavin.
Lastly, let us reiterate that a fu l chemical proce s leading from bound inhibitors to the final
inhibitor–F co plex involves three steps [52], hich would a l need to be considered if a complete
thermodynamic picture is desired. Still, the insight obtained here for the rate-limiting first step is
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already very informative and illustrative, while providing important guidelines in the design of more
effective and potent MAO irreversible inhibitors.
3. Materials and Methods
To calibrate our Empirical Valence Bond simulations of the enzyme inhibition reaction,
we performed the corresponding simulation of the nonenzymatic hydride transfer reaction in the
aqueous solution, which represented the reference process. The tunable EVB parameters, namely the
relative shift of potentials representing the reactant and product valence states (α0) and the coupling
parameter between these valence states (Hij), were obtained by fitting to the activation (∆G‡) and
reaction (∆GR) free energies obtained from the QM calculations in water solution, which is a valid
approach due to the demonstrated phase-independence of the EVB parameters [73]. The fitted EVB
parameters were then applied to the reaction simulation carried out in the fully featured environment
of the solvated MAO B enzyme (see below) to yield the free energy profiles presented here.
For the mentioned QM calculations in water, the structure of the FAD cofactor was truncated
to the lumiflavin (LMF) moiety (Figure 2, with the –CH2–S–Enzyme fragment replaced by –CH3),
while SEL and RAS were considered in full. The QM reaction energetics were calculated using the
M06–2X/6–31 + G(d,p) level of theory with the SMD implicit solvation employing parameters for
pure water, also used to obtain thermal corrections without the scaling factors, so that all computed
values corresponded to Gibbs free energies at a room temperature of 298.15 K and a normal pressure
of 1 atm. The validity of the obtained transition state structures was confirmed by the frequency
analysis (νimag = 1351i cm−1 for RAS and 1390i cm−1 for SEL) and the intrinsic reaction coordinate
(IRC) calculations. The reaction free energy was calculated as the difference between the energy of
the reactants complex and the transient intermediate point on the products reaction coordinate path
in which the hydrided LMFH− moiety remained planar, in line with our previous reports [56,74–76].
All QM calculations were performed using the Gaussian 16 program package [77].
The starting points for our EVB simulations were the coordinates of the MAO B enzyme in complex
with the bound NYP inhibitor (PDB ID: 1GOS) [34]. The inhibitor was removed, but its position in
this structure served as a reference point for the initial manual positioning of RAS and SEL into the
active site (Figure 5) using the UCSF Chimera program [78]. The protein model included one subunit
of the dimeric MAO B enclosed in a simulation sphere, with a 30 Å radius, centered at the reactive N5
atom of the FAD cofactor. Such a setup encompassed the vast majority of the protein—either RAS or
SEL—and 1662 TIP3P water molecules. All protein atoms outside this sphere were kept restrained to
their starting positions by applying a 200 kcal mol−1 Å−2 harmonic restraint. The simulations were
built around the OPLS-AA force field [79], with the ligand parameters acquired by the ffld_server
utility and assisted by the Maestro v. 11.7 graphical interface [80]. The charges of the ligand atoms were
determined by fitting to the electrostatic potential computed by QM calculations on the HF/6–31G(d)
level of theory according to the RESP scheme, as implemented in AmberTools18 [81]—all in line with
our previous reports [56–58,69,70,74–76,82,83].
The system was first equilibrated in several distinct steps, by slowly increasing both the temperature
(starting at 1 K and ending at 300 K) and the time-step (from 0.1 to 1 fs), as well as gradually removing
the restraints. An additional equilibration step of 10 ns was carried out at 300 K with minimal position
restraints. Such an equilibrated structure was used as the starting point for the subsequent simulations,
which employed standard EVB procedure based on the free energy perturbation/umbrella sampling
(FEP/US) approach [67,84,85]. In the case of FEP, the force fields which describe the valence states of
reactants and the products (Figure 2) must first be established. This force field was appropriately tuned
to allow for the breaking and formation of bonds, by replacing the harmonic potentials of the C–H and
N–H bonds with Morse functions, as well as substituting the 12-6 Lennard-Jones potential with a less
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restrictive Buckingham-type nonbonding potential on the three reacting atoms. The reactants were
then converted to the products in a series of mapping steps, using a mapping potential of the type [84]:
εm = λ·ε1 + (1 − λ)·ε2
where the force field of the reactants (ε1) was gradually transformed into the force field of the products
(ε2) via the coupling parameter lambda (λ). In our case, the initial structure was equilibrated at λ = 0.5
(i.e., a structure in the vicinity of the transition state). Thus, the subsequent FEP procedure was carried
out starting at λ = 0.5 and finishing at either λ = 0 or λ = 1, corresponding to reactants or the products
of the hydride abstraction reaction (Figure 2), and yielding 51 mapping steps. Each mapping step
was 100 ps long, totaling in 5.1 ns. Since the simulations were carried out in 10 independent replicas,
corresponding to different initial conformations of each inhibitor (each of which was first additionally
equilibrated for 100 ps), this gave us 51 ns of the total simulation time. All simulations were subject
to a cut-off of 10 Å for nonbonded interactions, except for the atoms in the EVB region (RAS or SEL
and the flavin moiety), which were subject to a much extended cut-off of 99 Å. Beyond that point,
the electrostatic interactions were treated with the local reaction field method. All FEP simulations
employed minimal restraints, necessary to obtain smooth free energy profiles, as discussed in our
previous studies [82,83], including a position restraint of 0.5 kcal mol−1 Å−2 within the EVB region,
with an additional restraint on the distance between the reacting inhibitor carbon (Cα) and FAD
nitrogen (N5) atoms (5.0 kcal mol−1 Å−2 for distances greater than 3 Å).
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in the active site. The position of the FAD cofactor is also shown in the stick representation.
A similar protocol was employed to generate EVB simulations in the aqueous solution, where the
equilibration runs were somewhat shorter, due to the smaller complexity of the environment compared
to the enzyme. The spherical simulation cell consisted of 3768 and 3762 water molecules for RAS and
SEL, respectively, and included the truncated lumiflavin moiety (LFN). The starting structures for all
simulations were generated using the qprep5 module, while all EVB molecular dynamics simulations
were carried out using the qdyn5 module of the Q program v. 5.06 [86], with its qfep5 module used for
the analysis of the trajectories and the VMD program [87] for their visualization. All calculations were
carried out at the Ažman Computing Center of the National Institute of Chemistry (Ljubljana, Slovenia).
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4. Conclusions
In this work, we performed a multiscale computational analysis of the initial rate-limiting step
of the irreversible inhibition of the MAO B enzyme by clinical inhibitors rasagiline and selegiline,
involving the hydride anion transfer from the inhibitor C(α) atom to the flavin co-factor N5 atom,
by using the state-of-the-art Empirical Valence Bond (EVB) QM/MM treatment. By properly including
fully featured solvated enzymatic environment, well converged free energy profiles were obtained that
gave the activation free energies of ∆G‡(RAS) = 27.6 and ∆G‡(SEL) = 24.5 kcal mol−1. The computed
values underline a higher reactivity of SEL, being in excellent agreement with the kinact data and the
experimentally determined ∆∆G‡ = 1.7 kcal mol−1 that point to the same conclusion. In line with
that, the calculated reaction free energies also favor the inhibition reaction with SEL, as the hydride
abstraction is significantly more exergonic with that inhibitor (∆∆GR = −8.2 kcal mol−1).
The obtained results strongly support the validity of the proposed hydride ion transfer as the
likely mechanism for the irreversible inhibition of MAO B with propargylamine inhibitors. In this way,
the acquired insight firmly confirms that both rasagiline and selegiline are mechanism-based inhibitors,
being strongly in line with experiments. The present study represents one of only a few attempts to
elucidate a molecular basis for the inhibition pathway of MAO enzymes, which bears a significant
relevance for neurology. In addition, the discussion presented here offers guidelines for a rational
design of new and more effective inhibitors, which are all clinically employed in treating a variety
of neuropsychiatric and neurodegenerative conditions. Additionally, such improved transition state
analogues are likely to be associated with less adverse effects, thus allowing for lower daily doses,
tying in with some of the most prominent challenges of modern medicine.
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